Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids are expected to supersede the standard therapy for Helicobacter pylori eradication. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains. Materials and Methods: A total of 140 strains were collected for a minimum period of 3 years. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations. Results: The resistance rate of clarithromycin was high, up to 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC50 and MIC90 of gentamicin (0.25 mg/L and 0.75 mg/L) and netilmicin (0.19 mg/L and 0.75 mg/L) were lower than other alternative therapies for H. pylori eradication. In clarithromycin-resistant strains, the MIC50 was 0.25 mg/L and the MIC90 was 1 mg/L for gentamicin; for netilmicin, the values were 0.25 mg/L and 0.75 mg/L, respectively. Conclusion: Through the use of gentamicin and netilmicin, which have low MICs for H. pylori, aminoglycoside-intercalated smectite hybrids are expected to emerge as a new standard therapy for H. pylori eradication.
Abstract
Background: Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids are expected to supersede the standard therapy for Helicobacter pylori eradication. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains. Materials and Methods: A total of 140 strains were collected for a minimum period of 3 years. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations. Results: The resistance rate of clarithromycin was high, up to 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC50 and MIC90 of gentamicin (0.25 mg/L and 0.75 mg/L) and netilmicin (0.19 mg/L and 0.75 mg/L) were lower than other alternative therapies for H. pylori eradication. In clarithromycin-resistant strains, the MIC50 was 0.25 mg/L and the MIC90 was 1 mg/L for gentamicin; for netilmicin, the values were 0.25 mg/L and 0.75 mg/L, respectively. Conclusion: Through the use of gentamicin and netilmicin, which have low MICs for H. pylori, aminoglycoside-intercalated smectite hybrids are expected to emerge as a new standard therapy for H. pylori eradication.
참고문헌 (33)
- Hooi JKY, "Global prevalence of Helicobacter pylori infection : systematic review and meta-analysis", Gastroenterology, 153, pp.420~429 (2017)
- Yim JY, "Seroprevalence of Helicobacter pylori in South Korea", Helicobacter, 12, pp.333~340 (2007)
- Lim SH, "Prevalence and risk factors of Helicobacter pylori infection in Korea : nationwide multicenter study over 13 years", BMC Gastroenterol, 13, pp.104~ (2013)
- Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
- Seta T, "Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: a systematic review and meta-analysis comparing risk ratio with risk difference", PLoS One, 12, pp.e0183321~ (2017)
- 허준, "한국에서 헬리코박터 파일로리에 대한 삼제요법의 치료율 변화", 대한소화기학회지, 63(3), pp.141~145 (2014), 대한소화기학회
- 김성은, "Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy", The Korean Journal of Internal Medicine, 30(6), pp.801~807 (2015), 대한내과학회[DOI]
- Lee JH, "Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults", Antimicrob Agents Chemother, 49, pp.1600~1603 (2005)
- Boyanova L, "Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents", Expert Rev Anti Infect Ther, 8, pp.59~70 (2010)
- Gasparetto M, "Helicobacter pylori eradication therapy : current availabilities", ISRN Gastroenterol, 2012, pp.186734~ (2012)
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- Chey WD, "American college of gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
- Venerito M, "Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection", Digestion, 88, pp.33~45 (2013)
- 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
- Graham DY, "Rational Helicobacter pylori therapy : evidence-based medicine rather than medicine-based evidence", Clin Gastroenterol Hepatol, 12, pp.177~186 (2014)
- Sugimoto M, "Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype", World J Gastroenterol, 20, pp.6400~6411 (2014)
- Draeger S, "Outcome of second-and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing", J Antimicrob Chemother, 70, pp.3141~3145 (2015)
- Hu Y, "Helicobacter pylori and antibiotic resistance, a continuing and intractable problem", Helicobacter, 21, pp.349~363 (2016)
- Fallone CA, "The Toronto consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
- Kumana CR, "Parenteral aminoglycoside therapy. Selection, administration and monitoring", Drugs, 47, pp.902~913 (1994)
- Amieva MR, "Host-bacterial interactions in Helicobacter pylori infection", Gastroenterology, 134, pp.306~323 (2008)
- Jeong SJ, "Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication", J Antimicrob Chemother, 73, pp.1324~1329 (2018)
- Irie Y, "Antibiotic MICs and short time-killing against Helicobacter pylori : therapeutic potential of kanamycin", J Antimicrob Chemother, 40, pp.235~240 (1997)
- Brenciaglia MI, "Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori", J Chemother, 8, pp.52~54 (1996)
- Valdez Y, "Antimicrobial susceptibility of Helicobacter pylori determined by the E test using tetrazolium egg yolk agar", J Clin Microbiol, 36, pp.2784~2785 (1998)
- Piccolomini R, "Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents", J Clin Microbiol, 35, pp.1842~1846 (1997)
- "Breakpoint- bacteria (v 8.0)"[URL]
- Hosaka Y, "Antibacterial activity of 16 antibiotics against Helicobacter pylori", Jpn J Antibiot, 53, pp.623~630 (2000)
- Wang C, "Role of interlayer hydration in lincomycin sorption by smectite clays", Environ Sci Technol, 43, pp.6171~6176 (2009)
- Li Z, "Interaction between tetracycline and smectite in aqueous solution", J Colloid Interface Sci, 341, pp.311~319 (2010)
- Trivedi V, "Intercalated theophylline-smectite hybrid for pH-mediated delivery", Drug Deliv Transl Res, 8, pp.1781~1789 (2018)
- Nanavaty J, "The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli", Curr Microbiol, 36, pp.212~215 (1998)
- Mattie H, "Determinants of efficacy and toxicity of aminoglycosides", J Antimicrob Chemother, 24, pp.281~293 (1989)